TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2

~ Inhaled Niclosamide Demonstrates Potent Activity Against Omicron Variant ~ Dosing of Inhaled Niclosamide Estimated to Produce Concentrations in Excess of Effective Dose ~ Expecting to Complete Phase 1 Safety and Pharmacokinetic Data of Inhaled Niclosamide by End of 1Q’22

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.



Please enter your comment!
Please enter your name here